ストックスクリーナーアプリを入手
5.175
3.81%
-0.205
前日終値:
$5.38
開ける：
$5.36
24時間の取引高:
95,398
Relative Volume:
0.31
時価総額：
$137.32M
収益：
$59.07M
当期純損益:
$-52.66M
株価収益率:
-2.5746
EPS:
-2.01
ネットキャッシュフロー:
$-40.16M
1週間 パフォーマンス:
+9.18%
1か月 パフォーマンス:
+0.68%
6か月 パフォーマンス:
-24.45%
1年 パフォーマンス:
-34.99%
1日の値動き範囲:
$5.0286
$5.36
1週間の範囲:
$4.75
$5.39
52週間の値動き範囲:
$4.3701
$11.30
Cvrx Inc Stock (CVRX) Company Profile
Compare CVRX vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
5.175 | 129.50M | 59.07M | -52.66M | -40.16M | -2.01 |
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-09 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2025-01-14 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2024-09-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-07-11 | 繰り返されました | Lake Street | Buy |
| 2024-05-01 | 再開されました | Craig Hallum | Buy |
| 2024-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-05-01 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 開始されました | Lake Street | Buy |
| 2022-07-18 | 開始されました | Craig Hallum | Buy |
| 2021-07-26 | 開始されました | Canaccord Genuity | Buy |
| 2021-07-26 | 開始されました | Piper Sandler | Overweight |
| 2021-07-26 | 開始されました | William Blair | Outperform |
すべてを表示
Cvrx Inc (CVRX) 最新ニュース
CVRx to Present at Canaccord Genuity’s 46th Annual Growth Conference - Quiver Quantitative
CVRx presentation will stream live from Boston on Aug. 11 - Stock Titan
CVRX|CVRx Inc|Price:4.870|Chg%:+0.130 - TradingKey
CVRx Inc (CVRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CVRx Inc (CVRX) Balance Sheet - TradingKey
CVRx Inc (CVRX) Institutional Confidence - TradingKey
CVRx Inc (CVRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CVRx Inc (CVRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CVRX|CVRx Inc|Price:4.740|Chg%:-0.150 - TradingKey
CVRx Inc (CVRX) Cash Flow - TradingKey
CVRX|CVRx Inc|Price:4.815|Chg%:+0.075 - TradingKey
CVRx Inc (CVRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CVRx (CVRX) Q4 2025 earnings summary - Quartr
CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026 - The Manila Times
CVRx Plans Aug. 6 Webcast on Second-Quarter Results - Stock Titan
CVRx Inc (CVRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CVRx (CVRX) Proxy filing Summary - Quartr
CVRx partners with Piedmont Columbus Regional Medical Center for first Barostim implant - Traders Union
CVRx (CVRX) The 44th Annual William Blair Growth Stock Conference Summary - Quartr
CVRx (CVRX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 Summary - Quartr
Craig-Hallum Maintains CVRx Inc(CVRX.US) With Buy Rating - 富途牛牛
CVRx Inc (CVRX) Stock Forum and Discussion - Moomoo
(CVRX) Risk Channels and Responsive Allocation - Stock Traders Daily
CVRx Inc(CVRX) Stock Options Chain | Quotes & News - Moomoo
CVRX Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Cleveland Clinic Florida adopts Barostim implant in collaboration with CVRx - Traders Union
CVRx Inc focuses on heart failure devices as investors watch Nasdaq listing - Ad-hoc-news.de
CVRx (CVRX) Piper Sandler 36th Annual Healthcare Conference Summary - Quartr
CVRx enables first commercial Barostim implant in Washington state for heart failure treatment - Traders Union
CVRx Inc focuses on cardiovascular innovation amid thin market signals - Ad Hoc News
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and CVRx (CVRX) - The Globe and Mail
CVRX Q1 2026 Earnings: EPS Beats Estimates as Loss NarrowsRevenue Breakdown Analysis - dars.gov.et
Lake Street Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Enterprise value to EBIT forward of CVRx, Inc. – NASDAQ:CVRX - TradingView
CVRX,INVA Volatility & Greeks - Finviz
CVRx shares rise on CMS inclusion for Barostim implant procedure - MSN
CVRx (CVRX) moves 11.6% higher: Will this strength last? - MSN
CVRX Q1 2026 Earnings: EPS Exceeds Estimates as Company Navigates Market ChallengesMid-Term Outlook - dars.gov.et
CVRx Inc. (CVRX) Sinks 13.5% as Selling Pressure Intensifies Near Key SupportKeltner Channel - dars.gov.et
CVRX Q1 2026 Earnings: EPS Beats Estimates Amid Operational ProgressEarnings Manipulation Risk - dars.gov.et
CVRx (CVRX) Moves 11.6% Higher: Will This Strength Last? - Yahoo Finance
CVRx Inc. Surges on Strong Trading Activity; Key Resistance Levels AheadTriple Bottom - dars.gov.et
Price to earnings forward of CVRx, Inc. – NASDAQ:CVRX - TradingView
Enterprise value to revenue forward of CVRx, Inc. – NASDAQ:CVRX - TradingView
Price to book forward of CVRx, Inc. – NASDAQ:CVRX - TradingView
CVRx, Inc. Actuals & Estimates (NASDAQ:CVRX) - TradingView
CVRX Forecast — Price Target — Prediction for 2027 - TradingView
(CVRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
CVRx stock up on Humana's Medicare coverage for Barostim therapy - MSN
CVRx Inc (CVRX) Stock Forecast & Analyst Ratings - Moomoo
CVRX Q1 2026 Earnings: EPS Beats Estimates as Pre‑Revenue Progress Drives Stock HigherEarnings Quality Analysis - dars.gov.et
Cvrx Inc (CVRX) 財務データ
収益
当期純利益
現金流量
EPS
Cvrx Inc (CVRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Hykes Kevin | PRES & CEO |
Mar 02 '26 |
Sale |
7.90 |
7,763 |
61,349 |
284,237 |
| VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,284 |
10,146 |
60,551 |
| OASHEIM JARED | CHIEF FINANCIAL OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,744 |
13,781 |
96,703 |
| John Robert Allen | Chief Revenue Officer |
Mar 02 '26 |
Sale |
7.90 |
3,964 |
31,326 |
86,036 |
| Jain Mudit K. | Director |
Feb 20 '26 |
Buy |
6.36 |
46,800 |
297,592 |
980,183 |
| Jain Mudit K. | Director |
Feb 18 '26 |
Buy |
4.64 |
600 |
2,785 |
5,650 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 26 '25 |
Sale |
10.03 |
6,337 |
63,560 |
4,040,861 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 24 '25 |
Sale |
10.06 |
2,200 |
22,132 |
4,047,198 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 21 '25 |
Sale |
10.00 |
500 |
5,000 |
4,049,398 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 12 '25 |
Sale |
10.00 |
1,000 |
10,000 |
4,049,898 |
1.04%
11.95%
大文字化:
|
ボリューム (24 時間):